Perrigo (NYSE:PRGO) Shares Down 4.8% – Time to Sell?

Perrigo Company plc (NYSE:PRGO) dropped 4.8% on Thursday . The stock traded as low as $10.75 and last traded at $10.63. Approximately 839,344 shares traded hands during trading, a decline of 72% from the average daily volume of 3,015,777 shares. The stock had previously closed at $11.17.

Analysts Set New Price Targets

PRGO has been the subject of several recent analyst reports. Weiss Ratings cut Perrigo from a “sell (d-)” rating to a “sell (e+)” rating in a report on Thursday, May 28th. Canaccord Genuity Group decreased their target price on shares of Perrigo from $20.00 to $17.00 and set a “buy” rating on the stock in a research report on Friday, February 27th. Zacks Research upgraded shares of Perrigo from a “strong sell” rating to a “hold” rating in a report on Monday, April 27th. Finally, Jefferies Financial Group reaffirmed a “hold” rating on shares of Perrigo in a research note on Thursday, February 26th. One analyst has rated the stock with a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the company presently has an average rating of “Hold” and an average target price of $19.33.

Perrigo Price Performance

The company has a 50 day simple moving average of $11.18 and a 200 day simple moving average of $12.45. The company has a market capitalization of $1.52 billion, a price-to-earnings ratio of -0.84, a price-to-earnings-growth ratio of 1.29 and a beta of 0.51. The company has a quick ratio of 1.59, a current ratio of 2.72 and a debt-to-equity ratio of 1.45.

Perrigo (NYSE:PRGO) last released its quarterly earnings data on Wednesday, May 6th. The company reported $0.43 earnings per share for the quarter, beating the consensus estimate of $0.39 by $0.04. The business had revenue of $841.80 million for the quarter, compared to analyst estimates of $1.04 billion. Perrigo had a positive return on equity of 9.96% and a negative net margin of 43.50%.The company’s revenue was down 7.2% compared to the same quarter last year. During the same period in the previous year, the company posted $0.60 EPS. Perrigo has set its FY 2026 guidance at 2.250-2.550 EPS. As a group, research analysts predict that Perrigo Company plc will post 2.11 EPS for the current year.

Perrigo Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 16th. Stockholders of record on Friday, May 29th will be given a $0.29 dividend. The ex-dividend date of this dividend is Friday, May 29th. This represents a $1.16 annualized dividend and a dividend yield of 10.6%. Perrigo’s dividend payout ratio is presently -8.85%.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the stock. EverSource Wealth Advisors LLC raised its holdings in shares of Perrigo by 116.0% during the 4th quarter. EverSource Wealth Advisors LLC now owns 1,888 shares of the company’s stock valued at $26,000 after buying an additional 1,014 shares during the period. Geneos Wealth Management Inc. grew its position in Perrigo by 439.1% in the first quarter. Geneos Wealth Management Inc. now owns 965 shares of the company’s stock valued at $27,000 after acquiring an additional 786 shares in the last quarter. UMB Bank n.a. raised its stake in shares of Perrigo by 161.5% during the fourth quarter. UMB Bank n.a. now owns 1,964 shares of the company’s stock valued at $27,000 after purchasing an additional 1,213 shares during the period. Meeder Asset Management Inc. acquired a new position in shares of Perrigo during the fourth quarter worth $28,000. Finally, CWM LLC boosted its stake in shares of Perrigo by 230.0% in the fourth quarter. CWM LLC now owns 2,191 shares of the company’s stock valued at $31,000 after purchasing an additional 1,527 shares during the period. 95.91% of the stock is owned by hedge funds and other institutional investors.

About Perrigo

Perrigo Company plc is a global healthcare supplier specializing in over-the-counter (OTC) and self-care products, as well as generic prescription pharmaceuticals and active pharmaceutical ingredients. The company develops, manufactures and distributes a broad array of consumer health products, including analgesics, vitamins and supplements, digestive health remedies, topical treatments, and infant formulas. Perrigo’s focus on private-label solutions has made it a leading partner for retailers and pharmacy chains seeking high-quality, value-oriented alternatives to branded medications and health supplements.

Organized across three principal business segments—Consumer Healthcare, Prescription Pharmaceuticals and Active Pharmaceutical Ingredients—Perrigo’s operations span research and development, manufacturing, quality assurance and global distribution.